Next Investors logo grey

Earnings upgrades and price target lift for Paragon Care

Published 08-SEP-2016 16:21 P.M.


2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

Paragon Care (ASX: PGC) delivered an outstanding performance in fiscal 2016, increasing revenues and net profit by 190% and 257% respectively.

This was assisted by the acquisitions of Designs for Vision, MediTron and Western Biomedical, initiatives that have not only provided additional revenue streams but have expanded the company’s geographic presence and product range.

Melbourne-based PGC is a leading provider of medical equipment, devices and consumables for the Australian and New Zealand healthcare market. Many of the products it offers have applications in treating conditions regularly found in the elderly, indicating that the company is leveraged to the ageing population thematic.

On this note the company distributes its products to aged care facilities, as well as the broader hospital and community care market.

Next Investors Image

In summing up fiscal 2016 John Hester from Bell Potter said, “PGC has transitioned from a subscale distributor into a vastly different proposition for investors seeking long-term earnings growth in the healthcare sector, without the regulatory risk typically associated with the sector via pricing, funding or compliance”.

However, it should be noted that analyst’s forecasts and price targets may not necessarily be met. Similarly, historical trading patterns should not be used as the basis for an investment decision as these may not be replicated in the future.

Importantly, strengthening of the business and a broadening of its distribution platform over the last two years has provided new avenues for management to explore in terms of continuing its growth by acquisition strategy.

PGC also has a healthy mix of products with good exposure to consumables that fall under the preventative services and maintenance areas, effectively providing income stability rather than relying on the sometimes unpredictable nature of the instrument and device distribution market.

Next Investors Image

Hester said he is expecting further acquisitions in fiscal 2017, noting that gearing was a very conservative 26%. He estimates the company has borrowing capacity up to approximately $40 million without the need to raise capital through an equity placement.

Taking into account the impressive fiscal 2016 result and the prospect of growth initiatives in the coming 12 months, Hester upgraded earnings per share forecasts for fiscal years 2017 and 2018 by 8.3% and 1.3% respectively.

He also upgraded the 12 month target price from 91 cents to 96 cents, implying a premium of circa 15% to Wednesday’s closing price of 82.7 cents.

Next Investors Image

This suggests there could be further upside in the group’s share price even after the significant spike that occurred in early August in response to the group’s results announcement.

PGC is trading on a fiscal 2017 PE multiple of 13 relative to Hester’s earnings forecasts. This appears conservative when compared with the high multiples usually attributed to companies in the healthcare sector. Furthermore, it doesn’t accurately reflect PGC’s growth prospects with Hester forecasting earnings per share accretion of 20% in fiscal 2017.

Next Investors Image

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.